In Patients with T2DM and Prior CVD, Only JARDIANCE® has Demonstrated Significant 38% Risk-Reduction for CV Death¹

Comparison of studies should be interpreted with caution due to differences in study design, populations and methodology

In Patient-subgroups with T2DM and CVD, Major CV Outcome Trials have Proven Some Similarities and Differences in Cardio-Renal and Mortality Outcomes with SGLT2-i

Adapted: McGuire DK et al. JAMA Cardiol. doi:10.1001/jamacardio.2020.4511. Published Online, Oct 7 2020. *Cherney DZI et al. Diabetologia. 2021 Jun;64(6):1256-17.